Sensex, Nifty Continue to Trade in Green; Consumer Durables & Energy Stocks Rally

Mon, 30 Oct 01:30 pm | Karan Janani, TM Team

   Previous Close   

   Pre-Open   

   09:30 am   

   11:30 am   

   Closing   

Indian share markets continued to trade well above the dotted line amid encouraging quarterly earnings. Gains were largely seen in consumer durables stocks, energy stocks and realty stocks.

The BSE Sensex is trading higher by 113 points and the NSE Nifty is trading higher by 45 points. Meanwhile, the BSE Mid Cap index is trading up by 1.2% & the BSE Small Cap index is up by 1.3%. The rupee is trading at 65.10 to the US$.

In news from the economy, as per an article in The Livemint, a ministerial panel has recommended lowering the goods and services tax (GST) rates for small businesses and extending the benefit to more such units to reduce their tax burden and improve compliance.

The changes in the so-called composition scheme could benefit millions of small enterprises, eateries and traders. As per the reports, the ministerial panel recommended a new tax rate under the composition scheme would be 1% for traders, manufacturers and restaurants from 1%, 2% and 5%, respectively earlier.

The panel also recommended increasing the ceiling for eligibility to enterprises with annual revenue of less than Rs 1.5 crore from Rs 1 crore currently.

Pharma stocks are trading on an optimistic note with Ajanta Pharma share price and Dr Reddy's lab share price leading the gains.

Cadila Healthcare share price is trading on an encouraging note (up 0.6%) after it received final approval from the US drug regulator to market Clobetasol Propionate ointment. The drug is used to treat variety of skin conditions like eczema, dermatitis and allergies etc. and it will be manufactured at its Ahmedabad facility.

Just Released: Multibagger Stocks Guide
(2018 Edition)

In this report, we reveal four proven strategies to picking multibagger stocks.

Well over a million copies of this report have already been claimed over the years.

Go ahead, grab your copy today. It's Free.

NO-SPAM PLEDGE - We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from The 5 Minute WrapUp with a few clicks. Please read our Privacy Policy & Terms Of Use.

Cadila Healthcare's formulations business spans India, US, Europe and emerging markets (mainly Brazil and South Africa). The company derived 34% and 41% revenues from India and the US, respectively, in FY17.

Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.

With an aim to lower the overall healthcare costs in the country, the US Food and Drug Administration (FDA) approved a record 763 generic drugs for the financial year ending 30th September. As per Mint Analysis, Indian pharma companies received 295 approvals accounting for 40% of the overall approvals during the year.

Generic Drug Approvals Hit The Roof

Even the total filings of abbreviated new drug applications (ANDAs) for generic drugs rose to 1,292 in FY17 from 852 in the previous year. While, faster approvals expedite the commercialisation of product pipelines of domestic pharma companies spurring growth.

At the same time however, it has raised the intensity of competition resulting in pricing pressures. The price erosion has been further compounded by a consolidation among US distributors and the decline in the number of products going off-patent over the past few years.

In another development, as per an article in The Economic Times, IDFC Bank and Shriram Capital are set to call off merger talks as both sides have failed to arrive at an acceptable valuation after four months of negotiations and regulatory misgivings.

As per the reports, the complex structure proposed by the managements involving at least four big entities engaged in transport and consumer financing and infrastructure funding. This stuttered various stakeholders who seemed to be pulling in different directions.

Reportedly, IDFC Bank was trying to find its feet in the fast-evolving, technologically driven banking industry after it got a licence in 2014. Shriram was keen on entering banking to reduce the risk of market volatility.

IDFC Bank share price was trading down by 1.5% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Indian Share Market Update: Top Gainers and Losers

What else is happening in the markets today? Dig in...